GlaxoSmithKline has entered into an agreement to divest full commercial rights to Wellbutrin XL in the U.S. to Biovail International Laboratories, for $510 million. GSK will retain existing rights to Wellbutrin XL for countries outside the U.S., excluding Canada. “We are actively reshaping our U.S. business and managing the transition occurring in our product portfolio,” said Deirdre Connelly, president North American Pharmaceuticals, GSK. “This transaction is one of a serie...